Immune thrombocytopenia during the COVID-19 pandemic
- PMID: 33855698
- PMCID: PMC8251163
- DOI: 10.1111/bjh.17457
Immune thrombocytopenia during the COVID-19 pandemic
Conflict of interest statement
EL, XL and MH have no disclosures. JBB has served on advisory boards and/or consulted for Amgen, Novartis, Dova, Rigel, UCB, Argenx, Momenta, Regeneron, RallyBio, and CSL‐Behring.
References
-
- Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596–606. - PubMed
-
- Bussel JCD, Cooper N, Dunbar C, Michel M, Rodeghiero F. COVID‐19 and ITP: Frequently Asked Questions. https://www.hematology.org/covid‐19/covid‐19‐and‐itp2020 [updated 2020, November 18].
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
